Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans
NCT03179163 · Penn State University · PHASE1/PHASE2 · terminated · last registry update 2024-02-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “COVID shut down human subjects research and then the grant funding expired” | – | Registry record, Penn State University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC12A3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-02-14Also stopped (terminated): Stadtspital Zürich, Furosemide + Metolazone (NCT05986773)
- 2024-10-10Results posted on the registry: University of New Mexico, Treatment of Furosemide + Hydrochlorothiazide + Treatment of Furosemide + Metolazone (NCT00690521)
- 2024-07-29Results posted on the registry: University of Iowa, Clonidine Pill + Hydrochlorothiazide (NCT03109795)
- 2024-07-29Also stopped (terminated): University of Iowa, Clonidine Pill + Hydrochlorothiazide (NCT03109795)
- 2024-07-15Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., Allisartan Isoproxil/Sustained-Release Indapamide + Allisartan Isoproxil (NCT06500689)
- 2024-05-22Results posted on the registry: VA Office of Research and Development, Hydrochlorothiazide (HCTZ) + Chlorthalidone (CTD) (NCT02185417)
- 2024-02-01Results posted on the registry: Insel Gruppe AG, University Hospital Bern, Placebo oral capsule + 12.5 mg hydrochlorothiazide (NCT03057431)
- 2023-12-12Phase 3 first posted: Johannes Grand, Acetazolamide + Metolazone 2.5 MG (NCT06166654)
- 2023-10-25Results posted on the registry: University of Texas Southwestern Medical Center, Potassium Magnesium Citrate (KMgCit) + Potassium Chloride (KCl) (NCT02665117)
- 2023-10-24Also stopped (terminated): Novartis, Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1 + Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 (NCT00170950)
- 2023-10-13Also stopped (withdrawn): Northwestern University, Amlodipine Besylate + Chlorthalidone (NCT05275907)
- 2023-09-22Results posted on the registry: Washington University School of Medicine, QUARTET LDQT + Candesartan (NCT03640312)
- 2023-08-21Results posted on the registry: Tulane University School of Medicine, amlodipine, hydralazine, terazosin or hydrochlorothiazide (NCT02046395)
- 2023-06-27Phase 3 first posted: Hospital Israelita Albert Einstein, candesartan cilexetil + chlorthalidone + amlodipine + Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) (NCT05920005)
- 2023-05-26Phase 3 first posted: Boryung Pharmaceutical Co., Ltd, Fimasartan + Indapamide + Fimasartan + Indapamide placebo (NCT05878561)
- 2023-05-03Also stopped (withdrawn): Ochsner Health System, Furosemide plus Chlorothiazide + Furosemide (NCT05840536)
- 2023-04-20Phase 3 first posted: Institut de Recherches Internationales Servier, Fixed [Per/Ind/Aml] + Free [Per/Ind + Aml] (NCT05820880)
- 2023-04-14Results posted on the registry: Gary L. Pierce, Clonidine + Hydrochlorothiazide (NCT01983462)
- 2023-04-14Also stopped (terminated): Gary L. Pierce, Clonidine + Hydrochlorothiazide (NCT01983462)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision